BlossomHill Oncology Drug Targeted EGFR C797S Mutation
BlossomHill Therapeutics presented encouraging efficacy data from its Phase 1/2 SOLARA trial, demonstrating a 45% objective response rate from BH-30643 in EGFR C797S-positive NSCLC…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
BlossomHill Therapeutics presented encouraging efficacy data from its Phase 1/2 SOLARA trial, demonstrating a 45% objective response rate from BH-30643 in EGFR C797S-positive NSCLC…
The FDA confirmed the pivotal study design, protocols for continued dosing, and co-primary endpoints for RP-A501, including a 12-patient efficacy population.
Connect Biopharma announced positive preliminary data from a global Phase 2 study of its asthma drug rademikibart, showing a 66% reduction in treatment failures at 28 days and sign…
NextEra Energy and Dominion Energy unveiled a strategic benefits package for Virginia, featuring unprecedented residential bill relief, a new headquarters in Richmond, and over 1,0…
Amended stake agreement adjusts board nomination thresholds to comply with NYSE American listing standards.
PricewaterhouseCoopers LLP consented to the incorporation by reference of their financial statements audit report regarding JRD Unico, Inc. into Sysco’s recent regulatory filings.
lululemon athletica inc. filed amended bylaws that explicitly permit board-chair and CEO to hold shareholder meetings solely by remote communication, a change made effective Septem…
Ingles Markets Inc has amended and restated its bylaws. The changes primarily address the corporation's registered office, principal office and related authority. The filing was su…
Contineum Therapeutics announced that the MOONLIGHT-1 trial evaluating JNJ-5120/PIPE-307 did not meet its primary efficacy endpoint for major depressive disorder, though the candid…
Stewards, Inc. filed an 8-K to amend the certificate of designation for its Series A Preferred Stock. The market implications are currently minimal as the filing confirms prior cor…
Zion Oil & Gas Inc filed an amendment to its Amended Bylaws, effective December 1, 2025, outlining corporate governance changes.
Biofrontera announced FDA approval of Ameluz for superficial basal cell carcinoma, expanding the therapy's market reach. This approval establishes it as the only FDA-approved photo…
Phio Pharmaceuticals announced a formal submission to the U.S. FDA regarding nonclinical and clinical data for PH-762, intending to progress to a Phase 2b trial. This filing is a k…
Summit's partner Akeso announced Phase III data showing ivonescimab significantly improved survival over pembrolizumab in PD-L1 positive patients, prompting the company to proceed …
Definium Therapeutics announced positive top-line results from its Phase 3 Panorama study of DT120 ODT in GAD, marking the third positive Phase 3 data readout for the drug and anti…
Scholar Rock receives FDA approval for ISEMBYLD, the first muscle-targeted therapy for SMA patients receiving SMN2-targeted treatments, with the product rollout already underway. T…
Telomir reported preclinical findings from The Ohio State University demonstrating Telomir-Zn inhibits cell growth in both human and canine osteosarcoma models, supporting parallel…
Soluna Holdings has secured a conditional Base Load classification for its 100 MW Project Dorothy campus in ERCOT Batch Zero. This follows a similar classification for Project Kati…
Cullinan reported positive Phase 3 REZILIENT3 results where zipalertinib plus chemotherapy significantly improved progression-free survival in first-line EGFR exon 20 insertion NSC…
Immunocore announced it achieved the enrollment goal for the TEBE-AM Phase 3 trial of KIMMTRAK in advanced melanoma. Topline data is expected as early as the end of 2026.